On Jul. 18, 2019, Chembio Diagnostics announced a collaboration with Shire Human Genetic Therapies, a wholly owned subsidiary of Takeda Pharmaceutical Company, a global pharmaceutical company, to develop a novel POC diagnostic test to detect an undisclosed biomarker.

Chembio will receive funding from Takeda, subject to satisfying certain milestones, to develop a quantitative POC test utilizing Chembio’s patented DPP platform and hand-held optical analyzer. The development of the POC test will build upon Takeda’s technical research on a unique set of biomarkers and is expected to provide quantitative results in approximately 15 minutes from a small 10ﾵL drop of fingerstick blood.